The Network Advantage: A Regulatory Perspective on Clinical Research Innovation
In this informative session, clinical trial professionals will have an opportunity to hear directly from the FDA’s David Burrow on ways industry can advance clinical trial innovation.
Federal News Update: NIH Funding, Vaccine Policy and Looming Drug Pricing Deadline
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC Launches “Access Granted”
Access Granted is the Association of Multisite Research Corporations’s (AMRC) initiative for increasing site participation at industry events. This month, we are giving away five free tickets to the inaugural Partnerships with Sites Summit, 15 September 2025, Philadelphia by entering our free prize giveaway.
Member spotlight: Javara: How a Mistaken Job Title Led Jennifer Byrne to a Life in Clinical Research
Derailed a bit at first to discover she’d in fact been hired as a clinical researcher, Byrne realized quickly. “I had found my life’s work.” Or, perhaps more accurately, it found her. And over three decades on, she’s CEO of Javara, a founding member of the Association for Multisite Research Corporations (AMRC) and a leading voice in clinical trial innovation.
Identifying the pain points that stop Sponsors and CROs from working with sites
In this candid conversation, representatives from the clinical trial ecosystem will discuss how they can work with sites more effectively. We will use the session to identify key issues and blockers that prevent Sponsors and CROs from engaging with multisite clinical research corporations (MCRCs).
Jennifer Byrne joins AMRC Board of Directors
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
Member spotlight: Pratia on building the future of clinical trials through technology and diversity
The prospect of finding new cures for patients is what drives Mona Alqam and her team at Pratia, a Research Site Network with 90+ sites across eight countries. With 1500+ Clinical Trials carried out since 2012 across approximately 85% of all Therapeutic Areas and protocol designs, Pratia has engaged in a wide spectrum of clinical trial activities.
As Pharma Pricing Pressures Hit All-Time High, MCRCs are Uniquely Positioned to Help
The word ‘bipartisan’ might have been sparsely used since January, but the issue of drug pricing has permeated both sides of the aisle over the last three years. The Biden Administration’s Inflation Reduction Act of 2022 marked a policy shift that empowered Medicare to re-negotiate pricing on some high-cost drugs for the first time. The Trump administration also signalled its stance on the issue last week, introducing a ‘Most Favored Nation’ (MFN) pricing model by way of executive order.
Member Spotlight: ALCANZA Clinical Works to Extend ‘Reach’ of Clinical Trials
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC welcomes Pratia as newest member, strengthening European representation
The Association of Multisite Research Corporations (AMRC) today announces Pratia, one of the largest and most respected site networks, has joined as the association’s fifteenth member. With this addition, AMRC now represents a collective footprint of nearly 500 research sites, almost 8,000 employees, and approximately 1,500 principal investigators across its member companies, globally.
